SCHEMBL902317

SCHEMBL902317

CCOC(=O)c1nc2ccnn2c(O)c1Oc1ccc(Cl)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.47
CYP1A2 P05177 1/20 0.43
NPBWR1 P48145 4/20 0.39
MCHR1 Q99705 3/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
LGALS8 O00214 2/20 0.38
LGALS3 P17931 2/20 0.38
NOTUM Q6P988 1/20 0.38
TARBP2 Q15633 3/20 0.37
GLP1R P43220 1/20 0.37
PDCD4 Q53EL6 1/20 0.36
MAOB P27338 1/20 0.36
CRHR1 P34998 2/20 0.36
NPC1 O15118 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902392 0.91 PDE4A (0.44) PDE4ANPBWR1MCHR1TARBP2
SCHEMBL902806 0.89 NPBWR1 (0.40) PDE4ANPBWR1MCHR1NOTUMCRHR1
SCHEMBL902416 0.81 HSP90AA1 (0.39) NPBWR1MCHR1CRHR1NPSR1
SCHEMBL902492 0.81 CRHR1 (0.38) NPBWR1MCHR1CRHR1NPSR1
SCHEMBL902329 0.80 PDE4A (0.47) PDE4AGABRA2GABRB2NOTUMTARBP2
SCHEMBL12126900 0.79 PDE4A (0.57) PDE4ACYP1A2GABRA2GABRB2TARBP2
SCHEMBL28790830 0.79 PDE4A (0.60) PDE4ACYP1A2TARBP2PDCD4NPC1
SCHEMBL902365 0.76 NPBWR1 (0.44) NPBWR1MCHR1CRHR1NPSR1
SCHEMBL31514460 0.74 PDE4A (0.52) PDE4ATARBP2MAOBNPC1
SCHEMBL902676 0.73 PDE4A (0.44) PDE4ATARBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 PDE4A 1751/4885CYP1A2 499/4885NPBWR1 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.